Analyzing MSC Industrial Direct (NYSE:MSM) and Cyclacel Pharmaceuticals (NASDAQ:BGMS)

MSC Industrial Direct (NYSE:MSM) and Cyclacel Pharmaceuticals (NASDAQ:BGMS) are both industrials companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, dividends, profitability, valuation, institutional ownership, earnings and analyst recommendations.

Analyst Ratings

This is a summary of recent ratings and recommmendations for MSC Industrial Direct and Cyclacel Pharmaceuticals, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MSC Industrial Direct	0	3	6	1	2.80
Cyclacel Pharmaceuticals	1	0	0	0	1.00

MSC Industrial Direct presently has a consensus price target of $133.22, indicating a potential upside of 13.40%. Given MSC Industrial Direct’s stronger consensus rating and higher probable upside, equities analysts plainly believe MSC Industrial Direct is more favorable than Cyclacel Pharmaceuticals.

Profitability

This table compares MSC Industrial Direct and Cyclacel Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
MSC Industrial Direct	5.55%	18.72%	10.57%
Cyclacel Pharmaceuticals	-118.27%	-31.60%	-27.72%

Volatility & Risk

MSC Industrial Direct has a beta of 0.83, suggesting that its share price is 17% less volatile than the S&P 500. Comparatively, Cyclacel Pharmaceuticals has a beta of -0.44, suggesting that its share price is 144% less volatile than the S&P 500.

Valuation & Earnings

This table compares MSC Industrial Direct and Cyclacel Pharmaceuticals”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MSC Industrial Direct	$4.01 billion	1.64	$222.59 million	$3.98	29.52
Cyclacel Pharmaceuticals	$750,000.00	5.95	-$3.00 million	($3.64)	-0.19

MSC Industrial Direct has higher revenue and earnings than Cyclacel Pharmaceuticals. Cyclacel Pharmaceuticals is trading at a lower price-to-earnings ratio than MSC Industrial Direct, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

79.3% of MSC Industrial Direct shares are owned by institutional investors. Comparatively, 23.6% of Cyclacel Pharmaceuticals shares are owned by institutional investors. 19.0% of MSC Industrial Direct shares are owned by insiders. Comparatively, 23.7% of Cyclacel Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

MSC Industrial Direct beats Cyclacel Pharmaceuticals on 13 of the 15 factors compared between the two stocks.

About MSC Industrial Direct

MSC Industrial Direct is a North American distributor of metalworking products and maintenance, repair and operations (MRO) supplies. The company serves manufacturers and other industrial customers, offering products such as cutting tools, abrasives, hand tools, safety equipment, fasteners and electrical supplies. In addition to product distribution, MSC provides services designed to help customers manage purchasing and inventory. These include online ordering, inventory-management programs, vending solutions and technical support for metalworking and manufacturing applications.

About Cyclacel Pharmaceuticals

Cyclacel Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing small-molecule medicines for the treatment of cancer. Its research programs are designed to target key proteins involved in tumor-cell growth, division and survival, with the goal of addressing cancers that have limited treatment options. The company’s pipeline has included fadraciclib (CYC065), an investigational selective cyclin-dependent kinase 2 inhibitor, and sapacitabine (CYC682), an oral nucleoside analog studied in several oncology indications.